RedHill Biopharma commences Phase III trial of RHB-105 to treat H. pylori infection

Israeli-based specialist biopharmaceutical firm RedHill Biopharma has commenced a confirmatory Phase III ERADICATE Hp 2 clinical trial of RHB-105 (Talicia) for the treatment of patients with Helicobacter pylori (H. pylori) infection.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news